Heru receives CES Innovations Award for re:Vive

The wearable device brings virtual and augmented reality into diagnostics

Heru Inc’s wearable diagnostics device, re:Vive, has been named a CES 2022 Innovation Award honoree in the virtual and augmented reality category. The announcement was made ahead of the technology conference CES 2022, which will be held in Las Vegas, Nevada, January 5-8.

Mohamed Abou Shousha, MD, PhD, FRSC, Heru’s founder, president, and CEO, said in a news release that the company is honored to receive such a prestigious award.

“re:Vive by Heru improves access to vision care and provides physicians with a single, space-saving diagnostic, health, and wellness tool [that] has revolutionized how screening and diagnosis for visual defects is performed in eye care,” Shousha said.

Re:Vive headsets

The re:Vive platform was designed in partnership with the University of Miami’s Bascom Palmer Eye Institute to enable developers to easily diagnose vision concerns in commercially available augmented reality/virtual reality head-mounted displays. The technology was selected from a pool of more than 1800 competitors for this year’s innovation award.

Heru’s headset is designed to provide an immersive, personal experience during examinations. A virtual personality onboards the patient wearer with guided support throughout the diagnostic process and encourages them to reach their clinical goals.

This technique allows clinicians to focus on their practice while allowing patients to take ownership of their treatment options. It also eliminates the need for follow-up visits and reviews.

Expansion

The company recently expanded its diagnostic platform to include 3 new testing modalities that enable physicians to perform 6 comprehensive examinations, supported with 5 reimbursable CPT codes, in a single wearable solution.

The expanded platform features a streamlined approach to diagnosis, which eliminates many legacy devices and provides physicians with new avenues to earn additional revenue.

“Screening for visual defects is only the beginning,” Frederic H. Moll, MD, chief development officer of robotics at Johnson & Johnson Medical Devices and an adviser at Heru, said in a news release. “In clinical development are therapeutic applications [that] include augmented vision correction. This new, cutting-edge technology will be the first of its kind and will transform the lives of patients with compromised vision around the world.”